EmbryoScope approved for sales in China
Vitrolife AB (publ) has today received market approval for the time-lapse incubator EmbryoScope in China and thereby becomes the first company to market an approved time-lapse incubator in the world´s largest IVF market.
EmbryoScope is a time-lapse system with an integrated incubator with a capacity for six patients. Vitrolife is the market leader of time-lapse systems for use in assisted reproduction for undisturbed culture and improved selection of embryos. “There is a great interest for time-lapse in China and we are delighted to now being able to offer EmbryoScope to the clinics in China”, says Thomas Axelsson, CEO of Vitrolife.
February 1, 2018
VITROLIFE AB (publ)
Thomas Axelsson, CEO
Queries should be addressed to:
Thomas Axelsson, CEO, tel 46 31 721 80 01
Mikael Engblom, CFO, tel 46 31 721 80 14
This information is information that Vitrolife AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, at 11.00 am CET on February 1, 2018.
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
Vitrolife is an international medical device Group. Vitrolife develops, produces and markets medical devices for assisted reproduction. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes.
Vitrolife has approximately 370 employees and the company's products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in Australia, Belgium, China, Denmark, France, Germany, Italy, Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ Stockholm.
Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: firstname.lastname@example.org. Website: www.vitrolife.com/